43.20
-1.75 (-3.89%)
| Previous Close | 44.95 |
| Open | 44.66 |
| Volume | 452,062 |
| Avg. Volume (3M) | 508,980 |
| Market Cap | 1,208,433,536 |
| Price / Sales | 7.93 |
| Price / Book | 114.73 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2025 |
| Profit Margin | -125.70% |
| Operating Margin (TTM) | -99.16% |
| Diluted EPS (TTM) | -4.76 |
| Quarterly Revenue Growth (YOY) | 286.80% |
| Total Debt/Equity (MRQ) | 1,016.89% |
| Current Ratio (MRQ) | 8.25 |
| Operating Cash Flow (TTM) | -108.78 M |
| Levered Free Cash Flow (TTM) | -60.04 M |
| Return on Assets (TTM) | -15.14% |
| Return on Equity (TTM) | -343.83% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | AnaptysBio, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | -3.5 |
| Price Volatility | -0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.5 |
| Average | -0.40 |
|
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 5.09% |
| % Held by Institutions | 133.99% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 100.00 (Guggenheim, 131.48%) | Buy |
| Median | 55.50 (28.47%) | |
| Low | 36.00 (Truist Securities, -16.67%) | Hold |
| Average | 62.38 (44.40%) | |
| Total | 7 Buy, 1 Hold | |
| Avg. Price @ Call | 40.82 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| UBS | 07 Jan 2026 | 70.00 (62.04%) | Buy | 45.21 |
| Barclays | 17 Dec 2025 | 55.00 (27.31%) | Buy | 45.69 |
| 11 Nov 2025 | 70.00 (62.04%) | Buy | 33.56 | |
| Stifel | 11 Dec 2025 | 56.00 (29.63%) | Buy | 45.78 |
| 29 Oct 2025 | 80.00 (85.19%) | Buy | 36.12 | |
| HC Wainwright & Co. | 24 Nov 2025 | 51.00 (18.06%) | Buy | 41.95 |
| 11 Nov 2025 | 52.00 (20.37%) | Buy | 33.56 | |
| Wedbush | 24 Nov 2025 | 50.00 (15.74%) | Buy | 41.95 |
| Truist Securities | 10 Nov 2025 | 36.00 (-16.67%) | Hold | 33.98 |
| Guggenheim | 05 Nov 2025 | 100.00 (131.48%) | Buy | 36.00 |
| Wells Fargo | 05 Nov 2025 | 81.00 (87.50%) | Buy | 36.00 |
| Show more | ||||
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| FAGA DANIEL | - | 44.07 | -38,792 | -1,702,879 |
| LIZZUL PAUL F. | - | 44.07 | -10,104 | -443,175 |
| LOUMEAU ERIC J | - | 44.36 | -14,832 | -661,443 |
| MARQUET MAGDA | - | 46.31 | -11,000 | -509,410 |
| MULROY DENNIS | - | 44.07 | -7,786 | -341,699 |
| Aggregate Net Quantity | -82,514 | |||
| Aggregate Net Value ($) | -3,658,606 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 44.31 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| MARQUET MAGDA | Director | 15 Jan 2026 | Sell (-) | 11,000 | 46.31 | 509,410 |
| MARQUET MAGDA | Director | 15 Jan 2026 | Option execute | 11,000 | - | - |
| FAGA DANIEL | Officer | 08 Jan 2026 | Sell (-) | 14,281 | 43.80 | 625,508 |
| LOUMEAU ERIC J | Officer | 08 Jan 2026 | Sell (-) | 2,210 | 43.80 | 96,798 |
| MULROY DENNIS | Officer | 08 Jan 2026 | Sell (-) | 2,515 | 43.80 | 110,157 |
| LIZZUL PAUL F. | Officer | 08 Jan 2026 | Sell (-) | 3,650 | 43.80 | 159,870 |
| MULROY DENNIS | Officer | 07 Jan 2026 | Sell (-) | 1,908 | 45.21 | 86,261 |
| FAGA DANIEL | Officer | 07 Jan 2026 | Sell (-) | 9,202 | 45.21 | 416,022 |
| LIZZUL PAUL F. | Officer | 07 Jan 2026 | Sell (-) | 2,235 | 45.21 | 101,044 |
| LOUMEAU ERIC J | Officer | 07 Jan 2026 | Sell (-) | 2,017 | 45.21 | 91,189 |
| LOUMEAU ERIC J | Officer | 07 Jan 2026 | Automatic sell (-) | 7,622 | 45.21 | 344,591 |
| FAGA DANIEL | Officer | 07 Jan 2026 | Option execute | 26,838 | - | - |
| LOUMEAU ERIC J | Officer | 07 Jan 2026 | Option execute | 5,888 | - | - |
| MULROY DENNIS | Officer | 07 Jan 2026 | Option execute | 6,700 | - | - |
| LIZZUL PAUL F. | Officer | 07 Jan 2026 | Option execute | 8,525 | - | - |
| MULROY DENNIS | Officer | 06 Jan 2026 | Option execute | 5,245 | - | - |
| FAGA DANIEL | Officer | 06 Jan 2026 | Option execute | 17,850 | - | - |
| LIZZUL PAUL F. | Officer | 06 Jan 2026 | Option execute | 6,145 | - | - |
| LOUMEAU ERIC J | Officer | 06 Jan 2026 | Option execute | 5,545 | - | - |
| LOUMEAU ERIC J | Officer | 05 Jan 2026 | Sell (-) | 2,983 | 43.20 | 128,866 |
| LIZZUL PAUL F. | Officer | 05 Jan 2026 | Sell (-) | 4,219 | 43.20 | 182,261 |
| MULROY DENNIS | Officer | 05 Jan 2026 | Sell (-) | 3,363 | 43.20 | 145,282 |
| FAGA DANIEL | Officer | 05 Jan 2026 | Sell (-) | 15,309 | 43.20 | 661,349 |
| Show more | ||||||
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |